Research Peptide Fundamentals research peptides: one evidence base, four legal categories

The short version

Buy Canadian Peptides is a reading desk, not a shop. It looks at four heavily discussed compounds — BPC-157, NAD+, semaglutide (Ozempic, Wegovy) and tirzepatide — and asks a question that usually gets skipped: why does the same molecule get a completely different legal answer depending on which country is asked?

The short answer is that approval is a legal decision about a filed application, not a scientific verdict on a molecule. A regulator rules on the dossier in front of it. Where nobody files, nothing is approved — and from the outside that silence looks identical to a refusal, even though the two mean opposite things.

So these four sit in four different categories. Two are approved prescription medicines. One is sold as a dietary supplement whose category is itself contested. One is not approved as a medicine anywhere and is sold for laboratory research use only. The underlying science barely moved while those lines were being drawn, which is the whole point of this desk.

About the name

The name of this site is a phrase people type into a search box, and it deserves a straight answer rather than a redirect. Buy Canadian Peptides is a jurisdiction question wearing the clothes of a transaction.

The jurisdiction half is real, and it is genuinely under-covered. National regulators do reach different conclusions about the same molecule; Canada's federal health regulator, Health Canada, operates a framework of its own; and the gap between two countries' decisions is one of the most misread facts in this whole subject.

The transaction half is not something this desk does. Nothing here is for sale. No seller, pharmacy, clinic or laboratory is named or recommended, in Canada or anywhere else. No route for obtaining a substance in one country while living in another is described, and no border procedure is described either — the personal legality of moving a medicine across a national border is a legal question with a country-specific answer, and a literature digest has no standing to give it.

A difference between two countries' approval decisions is a fact about paperwork. It is not an invitation.

What a research peptide actually is

Peptides are short chains of amino acids — the same building blocks that make proteins, only far smaller. Chemistry is where the family resemblance between the four compounds here ends.

BPC-157 is a synthetic fifteen-amino-acid peptide taken from a partial sequence of a protein found in human gastric juice. Semaglutide is a thirty-one-amino-acid analogue of the gut hormone GLP-1, sharing roughly 94% of its sequence and re-engineered at two positions plus a fatty-acid side chain so that it survives in the bloodstream long enough for a weekly schedule. Tirzepatide is a synthetic peptide too, but it engages two receptors at once rather than one. NAD+ is not a peptide at all — it is a dinucleotide coenzyme that every cell already makes.

NAD+ earns its place here precisely because it breaks the pattern. The phrase "research peptide" is a category of commerce and regulation rather than a category of chemistry, and NAD+ shows how loosely that phrase is applied: it sits in the same conversations, the same forums and the same regulatory arguments, while belonging to an entirely different chemical class.

Four compounds, four regulatory categories

Read by legal status rather than by mechanism, the four separate cleanly.

Approved prescription medicines. Semaglutide is approved by the US Food and Drug Administration across several indications and formulations — type 2 diabetes, chronic weight management, reduction of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and, in 2025, metabolic dysfunction-associated steatohepatitis — as both a once-weekly subcutaneous injection and a once-daily oral tablet. Tirzepatide was first approved in May 2022 for type 2 diabetes ^[18], with a later approval covering chronic weight management and a subsequent one covering moderate-to-severe obstructive sleep apnoea in adults with obesity.

Sold as a supplement, with the category under argument. NAD+ and its precursors, nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), are sold as dietary supplements. NMN's status is disputed: the FDA has taken the position that it is excluded from the dietary-supplement definition because it was investigated as a drug first. Injectable and intravenous NAD+ is typically compounded rather than approved, and one compounded NAD+ injection was subject to a Class I recall for elevated bacterial endotoxin.

Not approved anywhere. BPC-157 is not approved as a medicine in any jurisdiction and is distributed for laboratory research use only, explicitly not for human consumption. In 2023 the FDA placed it in a category of bulk drug substances it identified as not eligible for pharmacy compounding under section 503A, pending further evaluation. A 2025 narrative review treats it as investigational and notes that its availability runs through non-regulated channels ^[2].

A rule that ignores all of the above. The World Anti-Doping Agency prohibits BPC-157 in sport at all times under its category for non-approved substances — a category named for the absence of approval, which is why a national regulator's silence becomes a positive rule for an athlete. NAD+ and its precursors are not prohibited; neither semaglutide nor tirzepatide is specifically prohibited, although athletes are expected to verify current status independently.

Why the same molecule gets different answers in different places

Three mechanisms explain nearly all of the divergence, and none of them is scientific.

A regulator judges a dossier, not a molecule. An approval is a decision on an application somebody filed, with the evidence they chose to file. Absence from a country's approved list can mean the application failed, or that it was never made, or that it is still pending. Those look the same from outside and mean entirely different things.

Categories are legal, not chemical. NMN is the cleanest illustration on this desk. The dispute over whether it can be sold as a dietary supplement turns on whether it had previously been investigated as a drug — a fact about regulatory history, not about the compound. The molecule that would sit in a capsule is unchanged by the answer.

Availability moves without the evidence moving. During a federally declared shortage, compounding pharmacies in the United States produced semaglutide; the FDA documented dosing errors, adverse events requiring hospitalisation, and products with unverified or non-pharmaceutical active ingredients. When the shortage was declared resolved in 2025, those pathways were curtailed. Nothing about the molecule, and nothing in the trial record, changed in either direction.

Meanwhile the evidence base has no nationality at all. The trials that every regulator reads are the same trials: 17,604 participants in the cardiovascular outcome trial of semaglutide ^[13], 3,533 in the chronic-kidney-disease trial ^[12], 2,539 in the phase 3 obesity trial of tirzepatide ^[20], 1,879 in the head-to-head diabetes trial ^[21], and 751 in the head-to-head obesity trial ^[11]. One dataset, many verdicts. That gap — between a shared literature and a fragmented legal map — is what this site exists to describe.